home / stock / legn / legn news


LEGN News and Press, Legend Biotech Corporation From 05/14/24

Stock Information

Company Name: Legend Biotech Corporation
Stock Symbol: LEGN
Market: NASDAQ
Website: legendbiotech.com

Menu

LEGN LEGN Quote LEGN Short LEGN News LEGN Articles LEGN Message Board
Get LEGN Alerts

News, Short Squeeze, Breakout and More Instantly...

LEGN - Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

2024-05-14 08:45:00 ET Summary Legend Biotech Corporation reported lower-than-expected Q1 earnings, reflecting struggles in Carvykti’s revenue generation despite strong market potential. Carvykti, despite superior indications compared to competitors, is hindered by high tox...

LEGN - Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript

2024-05-13 12:13:02 ET Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript May 13, 2024 08:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Finan...

LEGN - Legend Biotech GAAP EPS of -$0.16 beats by $0.02, revenue of $93.99M misses by $47.37M

2024-05-13 07:04:49 ET More on Legend Biotech Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Scotiabank upgrades Legend Biotech to sector outperform Read the full article on Seeking Alpha For further details see: Legend Biot...

LEGN - Expected US Company Earnings on Monday, May 13th, 2024

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

LEGN - Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI ® label expansion in earlier lines of treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma Legend an...

LEGN - Legend Biotech Q1 2024 Earnings Preview

2024-05-10 12:45:29 ET More on Legend Biotech Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Legend Biotech Corporation (LEGN) Q4 2023 Earnings Call Transcript Legend Biotech Corporation 2023 Q4 - Results - Earnings Call Presentation ...

LEGN - Baron Opportunity Fund Q1 2024 Shareholder Letter

2024-05-02 10:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund rose 15.33%, outperforming the broade...

LEGN - US Companies Moving the Markets, Evening edition
Wed, Apr 24, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 179.3% to $0.4253 on volume of 213,352,319 shares Tesla Inc. (TSLA) rose 12.1% to $162.13 on volume of 179,967,315 shares PROSHARES TRUST (SQQQ) fell 0.8% to $11.81 on volume of...

LEGN - Baron Health Care Fund Q1 2024 Shareholder Letter

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

LEGN - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of C...

Previous 10 Next 10